Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat  by Szabo, Attila et al.
Kidney International, Vol. 57 (2000), pp. 982–991
Effect of angiotensin-converting enzyme inhibition on growth
factor mRNA in chronic renal allograft rejection in the rat
ATTILA SZABO, JENS LUTZ, KARINA SCHLEIMER, BALAZS ANTUS, PETER HAMAR,
THOMAS PHILIPP, and UWE HEEMANN
Departments of Nephrology and Surgery, University Hospital Essen, Germany, and Semmelweis Medical University,
Budapest, Hungary
Effect of angiotensin-converting enzyme inhibition on growth In recent years, chronic rejection has become a major
factor mRNA in chronic renal allograft rejection in the rat. cause of late renal graft loss after the first year [1]. Al-
Background. Despite considerable progress in immunosup- though chronic renal allograft rejection has been tradi-
pression, the incidence of chronic renal allograft rejection has
tionally regarded as a repeated low-grade response tonot decreased. Recent studies have revealed that angiotensin-
allogeneic tissue, recent evidence indicates that alloanti-converting enzyme (ACE) inhibition ameliorates graft arterio-
sclerosis, glomerulosclerosis, and tubular atrophy. Moreover, gen-independent factors may also contribute to its patho-
it decreases systemic and glomerular capillary hydrostatic pres- genesis [2–7]. These factors include surgical trauma, is-
sure in a rat kidney allograft model. We evaluated the effects chemia/reperfusion injury, cytomegalovirus infection,
of the ACE inhibitor enalapril on cytokine and growth factor
and donor age.expression in chronically rejecting rat kidney allografts.
Regardless of etiology, these factors contribute to theMethods. Kidneys of Fisher (F344) rats were orthotopically
reduction of nephrons in the single transplanted kidneytransplanted into Lewis (Lew) rats. To prevent acute rejection,
cyclosporine A (1.5 mg/kg/day) was given to all recipients dur- as compared with an intact organ, consequently inducing
ing the first 10 days after transplantation. Enalapril (60 mg/L) an imbalance between allograft nephron supply and the
or vehicle was added to the drinking water 10 days after trans- demands of the recipient, thereby stimulating hyperfunc-
plantation. Animals were harvested 20 weeks after transplanta-
tion and hyperfiltration in the remaining nephrons [8].tion for histologic and immunohistologic studies, as well as for
The remaining glomeruli have to adapt to the changedevaluation of cytokine and growth factor mRNA by semiquan-
microcirculation, resulting in an increased mean drivingtitative polymerase chain reaction.
Results. Controls developed severe signs of chronic rejec- force for glomerular capillary blood flow and capillary
tion, such as glomerular and vascular lesions, associated with pressure, and therefore a marked increase in the glomer-
a large number of infiltrating leukocytes. Enalapril-treated ani- ular filtration rate (GFR) [9, 10]. This hyperfiltrationmals developed less proteinuria and other signs of chronic
may result in endothelial activation followed by an up-rejection. The mRNA levels of transforming growth factor-b1
regulation of adhesion molecules [such as, intercellular(TGF-b1), platelet-derived growth factor A and B chain (PDGF
A and B), insulin-like growth factor-I (IGF-I), interleukin-1 adhesion molecule-1 (ICAM-1), vascular cell adhesion
(IL-1), and monocyte chemoattractant protein-1 (MCP-1) were molecule-1 (VCAM-1)] and a release of cytokines [in-
significantly reduced in the enalapril group and were most terleukin-1 (IL-1), tumor necrosis factor-a (TNF-a), in-
pronounced for IL-1 and PDGF A. In addition, we found an terferon-g (IFN-g), and monocyte chemoattractant pro-increased level of renal angiotensinogen mRNA after treat-
tein-1 (MCP-1)] and growth factors [insulin-like growthment with enalapril.
factor-I (IGF-I), platelet-derived growth factor (PDGF),Conclusions. Treatment with enalapril attenuated the devel-
opment of proteinuria, ameliorated morphological damage, and transforming growth factor-b1 (TGF-b1)], which in
decreased leukocyte infiltration, and prevented a rise in renal turn induce cell migration and proliferation of leukocytes
mRNA levels of growth factors and cytokines in kidney grafts and smooth muscle cells (SMCs), and play a causative
in a rat model of chronic renal allograft rejection.
role in extracellular matrix accumulation [11]. Moreover,
the local (endothelial) and systemic renin-angiotensin
system may be activated, thus causing posttransplantKey words: ACE inhibition, growth factors, chronic renal rejection,
enalapril. hypertension.
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pertensive nephropathy) or after renal transplantation excised, and perfused with 48C cold Ringer lactate. The
kidneys were then positioned orthotopically in anesthe-[12–14]. The increased efficacy of ACE inhibitors in ex-
perimental models and clinical trials as compared with tized, weight-matched Lew recipients whose left renal
vessels had been isolated, clamped, and the native kidneyother antihypertensive drugs is probably caused by a
reversal of angiotensin II-induced increase in resistance removed. Donor and recipient renal artery, vein, and
ureter were anastomosed end to end using 10-0 proleneat the efferent arteriole [15–17], and the influence on
growth and migration promoting cytokines [18]. The sutures. The contralateral native kidney was removed
on the 10th postoperative day.therapeutic effects of ACE inhibitors are independent
of their systemic antihypertensive effects since they can
Experimental protocolbe observed in normotensives [19, 20]. Moreover, they
reduce proteinuria more effectively in chronic renal dis- To overcome infectious complications caused by oper-
ation and immunosuppression, rats received Cephtriax-ease compared with b blockers or calcium antagonists
while having the same blood pressure-lowering effect [21]. one (Rocephint, 20 mg/kg/day; Hoffmann-La Roche
AG, Grenzach-Wyhlen, Germany) during the first 10Angiotensin II acts as a growth factor for glomerular
and tubular cells [22] and may directly induce collagen postoperative days. To prevent an initial episode of acute
rejection, rats received 1.5 mg/kg/day cyclosporine Asynthesis, an effect mediated by TGF-b1 and PDGF-A
[18]. Additionally, angiotensin II stimulates the adhesion (Novartis GmbH, Nu¨rnberg, Germany) for the first 10
postoperative days. Transplanted animals receivedof mononuclear cells to mesangial cells and the chemo-
taxis of macrophages and lymphocytes [23]. Therefore, either normal drinking water (controls, N 5 10) or 60
mg/L enalapril (MSD, Haar, Germany; enalapril group,in renal transplant recipients, ACE inhibition may not
only effectively lower systemic blood pressure, but may N 5 10). As additional controls, a group of 12 Lew rats
was sham operated and treated with cyclosporine A foralso be antiproliferative and antimigrative as it reduces
the release of cytokines and growth factors [16–25]. 10 days.
Body weights and proteinuria were measured onceOur present study was designed to determine the ef-
fects of the ACE inhibitor enalapril on the occurrence per month. After 20 weeks, rats were anesthetized with
diethylether and bled, and the transplanted kidneys wereand progression of chronic renal allograft rejection in
the Fischer/Lewis model, as a standard transplant model removed. Samples were snap frozen in liquid nitrogen
for immunohistological staining and polymerase chainfor chronic rejection of the kidney in rats. This model
is characterized by tubular atrophy, interstitial fibrosis, reaction (PCR) or fixed in formalin (4%) for light micros-
copy.intimal thickening of graft arteries, and glomerulosclero-
sis accompanied by severe proteinuria. Moreover, we
Functional measurementsinvestigated the effects of ACE inhibition on the mRNA
levels of growth factors and cytokines in rats with chronic Twenty-four–hour urine samples were collected every
four weeks. Urinary protein and creatinine excretion, askidney allograft rejection.
well as serum creatinine concentrations, was determined
photometrically with commercially available test kits,
METHODS
and the creatinine clearance was calculated at the end
Animals of the study.
Experiments were performed with male inbred Fisher
Histology(F344) and Lewis (Lew) rats with a body weight between
180 and 250 g. All animals were obtained from Charles For histology, kidney tissues were fixed in 4% buffered
formalin, embedded in paraffin, and stained with hema-River (Sulzfeld, Germany) and housed in standard plas-
tic cages and maintained in a temperature- and humidity- toxylin and eosin. The periodic acid-Schiff reaction was
performed to evaluate the extent of glomerulosclerosis.controlled environment. The animals had access to stan-
dard chow food and tap water ad libitum. All experi- It was defined as a collapse of capillaries, adhesion of
the obsolescent segment of Bowman’s capsule, and thements were approved by a governmental committee on
animal welfare. entrapment of hyaline [26]. At least 200 glomeruli were
counted in each kidney section, and the proportion of
Renal transplantation sclerosed to total glomeruli was expressed as a per-
centage.Fisher (F344) rats served as donors, and Lew rats
served as recipients. Under ketamine (100 mg/kg body
Antibodieswt, intraperitoneally; Ketamin 10%; cp-pharma, Burg-
dorf, Germany), plus xylacine (10 mg/kg body wt, i.p.; Monoclonal antibodies against macrophages (ED1),
CD51 T-lymphocytes (OX19), ICAM-1 (CD-54), andRompunt; Bayer, Leverkusen, Germany) anesthesia,
the left kidney of each F344 donor rat was isolated, VCAM-1 (CD-106) were purchased from Serotec Ca-
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mon Labor-Service GmbH (Wiesbaden, Germany). The ribonuclease inhibitor (Promega, Madison, WI, USA),
secondary rabbit antimouse antibody and the alkaline and 0.5 mL of 200 U/mL M-MLV reverse transcriptase
phosphatase antialkaline phosphatase (APAAP) com- (GIBCO BRL) was added, and the first chain reaction
plex were obtained from Dako A/S (Hamburg, Ger- was allowed to proceed (368C, 1 h). The reaction was
many). halted by heating to 958C for five minutes followed by
cooling on ice.
Immunohistology
Representative portions of kidney grafts were snap Amplification of specific complementary DNA
frozen in liquid nitrogen, cut with a cryostat (4 mm),
Specific complementary DNA (cDNA) products cor-fixed in acetone at 48C for five minutes, air dried, and
responding to mRNA for TGF-b1 [28], PDGF-A chainstained with the respective antibodies. After incubation
[29], MCP-1 [30], IGF-I [31], IL-1 [32], angiotensinogenwith the primary antibody, the sections were incubated
[33], and glyceraldehyde-3-phosphate dehydrogenasewith rabbit antimouse IgG and with the APAAP com-
(GAPDH) [34] were amplified using PCR. One milliliterplex. ICAM-1– and VCAM-1–like immunoreactivity
from the RT reaction was taken for PCR, which waswere quantitated on a grade 1 to 3 scale (1 5 mild, 2 5
performed in PCR buffer (750 mmol/L Tris hydrochlo-moderate, 3 5 strong). Positive cell counts for macro-
ride, pH 9.0, 200 mmol/L (NH4)2SO4, 0.1% (wt/vol)phages (ED1) and T-lymphocytes (OX19) were ex-
Tween 20, 20 mmol/L magnesium dichloride (Dianova,pressed as a mean 6 SEM of cells per field of view
Hamburg, Germany) using 0.2 mmol/L of each deoxy-(c/FV); .20 FV/section/specimen were evaluated at
3400. nucleoside triphosphates, 1 mmol/L of both primers (Eu-
rogentec, Ko¨ln, Germany), and 2.5 U thermus Aquaticus
Total RNA isolation (Taq) DNA polymerase (Dianova, Hamburg, Ger-
Total RNA was extracted and used for reverse tran- many). A Perkin Elmer Thermal Cycler (Model 2400;
scriptase-PCR (RT-PCR). Kidney tissue was stored in Perkin Elmer, Norwalk, CT, USA) was used for amplifi-
500 mL of cold lysis solution containing 4 mol/L guani- cation with the following sequence profile: initial dena-
dine isothiocyanate (Sigma, St. Louis, MO, USA), 25 turation at 948C for three minutes, followed by 30 to 35
mmol/L sodium citrate (pH 7.0), 0.1 mol/L b-mer- cycles of three temperature PCRs (denaturing, 948C for
captoethanol, 0.5% sarcosyl and frozen in liquid nitrogen. 30 s; annealing, 558C for 30 s; and extension, 728C for
Total RNA was extracted from the kidneys according to 30 s), ending with a final extension at 728C for seven
the modified guanidine-isothiocyanate preparation [27].
minutes and cooling to 48C.Briefly, frozen tissues were mixed with 4 mL GITC buffer
(4 mol/L guanidine isothiocyanate; Sigma) and acid phe-
Gel electrophoresisnolchloroform (pH 4, Roth), and homogenized. The
The amplified PCR product was identified by electro-samples were centrifuged at 1500 g for 10 minutes at
phoresis of 10 mL sample aliquots on 1.5% agarose gel208C. The supernatant was added to an equal volume of
stained with 0.5 mg/mL of ethidium bromide. The sampleisopropanol followed by centrifugation. The RNA was
products were visualized by ultraviolet transillumination,purified with the Rneasy, Total RNA Isolations Kit (Qia-
gen GmbH, Hilden, Germany), and stored at 2808C and the gel was photographed. Specific products were
until further processing. The RNA concentration was identified by size in relationship to a known 1 kb oligonu-
measured spectrophotometrically. cleotide DNA ladder (GIBCO BRL) run with each gel.
Cytokine cDNA was semiquantitated by densitometric
Reverse transcription comparison with GAPDH (internal control) from the
RNA was amplified by RT with an Oligo(dT)12-18 same sample after the positive image was digitized by
primer (GIBCO BRL, Karlsruhe, Germany). One milli- video for computerized densitometry. The results are
gram of total RNA was added to 0.5 mg of primer. A given as the ratio of intensity of growth factors or cyto-
reaction mixture containing buffer solution [Tris hydro- kines to GAPDH mRNA 6 SEM.
chloride buffer in a concentration of 50 mmol/L (pH 8.3),
potassium chloride in a concentration of 75 mmol/L, Statistical analysis
magnesium dichloride in a concentration of 5 mmol/L,
Results are expressed as mean 6 SEM. For statisticaldithiothreitol in a concentration of 5 mmol/L; GIBCO
analysis, a paired Student’s t-test was used. NonmetricBRL], adenosine triphosphate, thymidine triphosphate,
parameters such as the intensity of staining for adhesionguanosine triphosphate, and cytosine triphosphate each
molecules were evaluated with Fischer’s exact test forin a concentration of 0.2 mmol/L (deoxynucleoside tri-
ordinal data [35]. A P value of ,0.05 was considered tophosphates from Boehringer Mannheim GmbH, Mann-
heim, Germany), 0.5 mL of 40 U/mL of recombinant be statistically significant.
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Table 1. Urinary protein excretion in controls and enalapril treated rats four to 20 weeks after transplantation
24-Hour protein excretion mg/dl
Group 4 weeks 8 weeks 12 weeks 16 weeks 20 weeks
Controls N 5 10 2369.2 34615.7 37619.8 37628.9 7167.3
Enalapril N 5 10 24613.7 2065.7 2665.7 24615.1 27612.2a
Sham-operated N 5 10 1664.1 1362.9 1964.8 2363.3 2568.9
a P , 0.05 controls vs. enalapril
RESULTS with the enalapril-treated group. In the control group,
three animals had no tubular atrophy. Four animals hadFunctional measurements
grade 1, and three animals showed a grade 2 tubularWhile controls developed significant and progressive
atrophy. In the enalapril-treated group, five animals hadurinary protein excretion after 16 weeks, enalapril-
no tubular atrophy. Five had grade 1, and no animaltreated recipients had minimal urinary protein excretion
displayed a grade 2 or 3 tubular atrophy (Table 2). Theseduring the entire 20-week follow-up period (at 20 weeks
results did not differ statistically between the two groups.48 6 3.6 vs. 23 6 0.73 mg/24 h, P , 0.05; Table 1).
Intimal proliferation. There was a trend toward moreCreatinine clearance did not differ significantly between
severe intimal proliferation in controls as compared withthe two groups at the end of the 20-week follow-up
enalapril-treated animals. In the control group, two ani-period (controls 1.5 6 0.1 mL/min vs. treated 1.6 6 0.1
mals did not demonstrate intimal proliferation. Six ani-mL/min). Sham-operated animals did not develop any
mals had grade 1, and two grade 2 intimal proliferation.significant proteinuria.
In enalapril-treated animals, grade 1 intimal prolifera-
Mean arterial blood pressure tion was evident in four animals, while all others had no
intimal proliferation. These results were not statisticallyThe mean arterial blood pressure was not significantly
different between control and enalapril-treated animals different between the two groups (Table 2).
(94 6 10.2 vs. 90 6 8.9 mm Hg). Immunohistology. At week 20, mononuclear cell in-
filtration was apparent in both groups. Cellular infiltra-
Body weight tion was most intense in interstitial areas, particularly
Body weight tended to be lower in controls as com- around vessels and glomeruli. Whereas some lympho-
pared with enalapril-treated animals (419 6 15 vs. 429 6 cytes surrounded Bowman’s capsule, almost none were
11 g). observed within the glomeruli. Only macrophages
could be detected within the glomerular tuft. The num-
Histology
ber of macrophages and lymphocytes was significantly
All transplants developed changes of chronic rejection reduced in the treated group as compared with controls
such as glomerulosclerosis, interstitial fibrosis, tubular (Table 3).
atrophy, and intimal proliferations of graft arteries dur- The presence of leukocytes was associated with a
ing the observation period [11, 36, 37]. However, the strong immunoreactive signal of adhesion molecules
degree differed between the groups; treatment with ena- (ICAM-1, VCAM-1). The ICAM-1–like immunoreac-
lapril significantly ameliorated signs of chronic rejection, tive signal was predominantly higher on endothelial cells
particularly glomerulosclerosis (Table 2 and Fig. 1).
of small vessels, mesangial cells, and tubular epithelial
Glomerulosclerosis. Glomerulosclerosis was signifi-
cells, whereas VCAM-1–like immunoreactivity was mostcantly higher in controls (26 6 1.7%) than in enalapril-
pronounced on tubular epithelial cells. Treatment withtreated animals (19 6 1.8%, P , 0.05).
enalapril significantly reduced the immunoreactive signalInterstitial fibrosis. Animals in the control group had
of both adhesion molecules (P , 0.01; Table 3). TGF-significantly more interstitial fibrosis as compared with
b–like immunoreactivity was mainly found on interstitialthe enalapril-treated animals (P , 0.05). In the control
cells within the grafts. The number of cells with TGF-group, one animal had no signs of interstitial fibrosis.
b–like immunoreactivity was low in treated and controlThree had grade 1 fibrosis. Six had grade 2, and no
animals with a tendency toward a higher number in ani-animals developed grade 3 fibrosis. In the enalapril-
mals with moderate fibrosis and was confined to intersti-treated group, five animals had no signs of interstitial
tial cells within the graft.fibrosis. Five animals had grade 1 fibrosis, and no animal
Sham-operated animals developed no signs of chronicdisplayed grades 2 or 3 fibrosis (Table 2).
rejection, neither histologically nor immunohistologi-Tubular atrophy. There was a trend toward more se-
vere tubular atrophy in the control group as compared cally.
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Table 2. Glomerulosclerosis, interstitial fibrosis, vasculopathy, and tubular atrophy according to the Banff ’97 classification
Interstitial fibrosis Tubular atrophy Intimal proliferation Glomerulopathy
Glomerulosclerosis
%Group grade 5 N
Controls N 5 10 2661.7 grade 0 5 1 grade 0 5 3 grade 0 5 2 grade 0 5 4
grade 1 5 3 grade 1 5 4 grade 1 5 6 grade 1 5 4
grade 2 5 6 grade 2 5 3 grade 2 5 2 grade 2 5 2
grade 3 5 0 grade 3 5 0 grade 3 5 0 grade 3 5 0
Enalapril N 5 10 1961.8a grade 0 5 5 grade 0 5 5 grade 0 5 6 grade 0 5 5
grade 1 5 5 grade 1 5 5 grade 1 5 4 grade 1 5 5
grade 2 5 0 grade 2 5 0 grade 2 5 0 grade 2 5 0
grade 3 5 0 grade 3 5 0 grade 3 5 0 grade 3 5 0
Sham-operated N 5 10 560.4a grade 0 5 9 grade 0 5 10 grade 0 5 10 grade 0 5 9
grade 1 5 1 grade 1 5 0 grade 1 5 0 grade 1 5 1
grade 2 5 0 grade 2 5 0 grade 2 5 0 grade 2 5 0
grade 3 5 0 grade 3 5 0 grade 3 5 0 grade 3 5 0
aP , 0.05 controls vs. enalapril
Growth factor mRNA levels model render the possibility that the observed histologic
changes are due to cyclosporine A nephrotoxicity highlyGrowth factor mRNA levels paralleled the develop-
unlikely. Thus, it came as no surprise that sham-operatedment and progression of interstitial fibrosis and glomeru-
animals did not develop any signs of chronic rejection.losclerosis [3, 37, 38] 20 weeks after transplantation.
This confirms the results of our previously publishedPDGF-A chain mRNA levels were fourfold higher in
experiments [43, 44].controls than in enalapril-treated animals. TGF-b1 In our study, controls developed massive 24-hour pro-mRNA levels in the enalapril-treated group were 1.6-
tein excretion 20 weeks after transplantation. The admin-fold lower than in controls. Additionally, treatment with
istration of enalapril resulted in a significantly reducedenalapril significantly reduced the mRNA levels of
24-hour protein excretion. The mechanisms involved are
PDGF-B chain and IGF-I (1.5-fold; Fig. 2). hypothesized to be an intraglomerular and/or a direct
The mRNA levels of MCP-1, a potent chemotactic ACE inhibitory effect on glomerular cells. In rats, intra-
factor specific for monocytes/macrophages and a contrib- glomerular hypertension is thought to induce protein
utor of chronic inflammatory responses [39], was also loss by the formation of large, nonselective pores in the
significantly lower in the enalapril-treated group (Fig. glomerular wall, prior to the development of glomerulo-
2). MCP-1 mRNA levels paralleled the number of mono- sclerosis [45]. Micropuncture studies suggest that low-
nuclear cells infiltrating the graft. ering the glomerular capillary hydraulic pressure by
The expression of the monocyte/macrophage product ACE inhibition reduces proteinuria by a reduction of
IL-1b mRNA, also implicated in the development of the number of large pores in the glomerular wall [14,
sclerosis and fibrosis, was significantly reduced (2.5-fold) 46]. Therefore, this effect might protect the kidney from
in the enalapril-treated group as compared with controls further damage and thus prevent the progression of renal
(Fig. 2). As with MCP-1, the decreased level of IL-1b disease. In addition, Amann et al demonstrated in a
subtotal nephrectomy model in rats that ACE inhibitors,mRNA correlated to a decreased number of macro-
but not other antihypertensive drugs, prevented podo-phages. Angiotensinogen mRNA levels were signifi-
cyte injury closely associated with the reduction of pro-cantly higher in enalapril-treated animals as compared
teinuria [47]. Lewis et al demonstrated a more pro-with controls (P , 0.05; Fig. 2).
nounced reduction of proteinuria in patients with chronic
renal disease with ACE inhibitors as compared with pa-
tients treated with calcium antagonists or b blockers,DISCUSSION
although the blood pressure-lowering effect was similar
The beneficial effects of ACE inhibition on the pro- in all groups [21].
gression of renal disease and chronic renal allograft rejec- In controls of the present experiment, progressive glo-
tion have been demonstrated in different animal models merulosclerosis and severe glomerular as well as intersti-
[25, 40–42]. However, the precise mechanisms of action tial infiltration of macrophages and lymphocytes were
remained unknown. Our present study demonstrated de- observed, whereas these changes were markedly reduced
creased levels of growth factor mRNA in transplanted in the enalapril group. These findings could be related to
rat kidneys following ACE inhibition, associated with a modification of proliferative and immunomodulatory
attenuation of chronic renal allograft rejection. The very signals mediated by angiotensin II. Angiotensin II has
been reported to have immunoregulating effects, suchshort time and low dose of cyclosporine A used in our
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Fig. 1. Effect of enalapril on development of
glomerulosclerosis and cell infiltration. Rep-
resentative sections of kidney allografts from
enalapril-treated (A) and untreated (B) ani-
mals (PAS reaction; 3100).
Table 3. Lymphocyte and macrophage infiltration, and quantification of extracellular matrix deposition for adhesion molecules
(ICAM-1 and VCAM-1) in transplanted kidney
Lymphocytes Macrophages ICAM-1 VCAM-1
Group cells/FV grade 5 N
Controls N 5 10 5862.5 6763.4 grade 1 5 1 grade 1 5 1
grade 2 5 2 grade 2 5 2
grade 3 5 7 grade 3 5 7
Enalapril N 5 10 4661.9a 3262.2a grade 1 5 4 grade 1 5 4
grade 2 5 4 grade 2 5 5
grade 3 5 2 grade 3 5 1
Sham-operated N 5 10 1263.8 1564.3 grade 1 5 8 grade 1 5 7
grade 2 5 2 grade 2 5 3
grade 3 5 0 grade 3 5 0
Abbreviation FV is field of view.
aP , 0.01 controls vs. enalapril; differences in ICAM-1 and VCAM-1 were statistically different (P , 0.01)
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Fig. 2. Growth factor and cytokine mRNA
levels in renal allografts 20 weeks after trans-
plantation (N 5 10). Panels are: (A) platelet-
derived growth factor (PDGF)-A chain; (B)
PDGF-B chain; (C) transforming growth fac-
tor-b1 (TGF-b1); (D) insulin-like growth
factor-I (IGF-I); (E) interleukin-1 (IL-1);
(F ) monocyte chemoattractant protein-1
(MCP-1); (G) angiotensinogen (*P , 0.05).
as leukocyte adhesion and chemotaxis [48, 49]. Ruiz- adhesion promoting and chemoattractant effects of an-
giotensin II remains unclear thus far.Ortega et al observed a significant reduction in glomeru-
lar and interstitial infiltration in rats with immune com- Chemoattractants for monocytes/macrophages in-
clude MCP-1 and TGF-b1. Both play a major role inplex nephritis treated with the ACE inhibitor quinalapril
[42]. However, how ACE inhibition interferes with the chronic renal allograft rejection [39] and chronic in-
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flammatory responses, as observed in transplant vasculo- Furthermore, we demonstrated that enalapril also re-
duced the expression of IGF-I mRNA, a chemoattrac-pathy [39]. Moreover, MCP-1 may also activate or in-
crease the expression of adhesion molecules and thus tant for SMCs with fibrotic activity. Recently, angioten-
sin II has been shown to exert proapoptotic andfacilitate monocyte adhesion. In this experiment, similar
to the observations of Nadeau, Azuma, and Tilney [39], antiapoptotic effects in various cell types, including
SMCs [55]. In addition, ACE inhibitors have been re-a progressive increase in MCP-1 mRNA levels was de-
tected in kidney allografts, preceding macrophage infil- ported to enhance apoptosis that occurred in association
with regression of vascular growth, as a part of theirtration. In the present study, long-term enalapril treat-
ment significantly decreased the expression of MCP-1 antihypertensive and/or antihypertrophic effect [58].
Apart from a reduced angiotensin II formation, ACEand TGF-b1 levels. TGF-b–like immunoreactivity was
mainly localized to interstitial cells within the graft. inhibition also increases bradykinin concentrations, with
the subsequent generation of nitric oxide and prostaglan-These results were paralleled by a significantly reduced
expression of ICAM-1 and VCAM-1 in the enalapril dins. Thus, the beneficial effects of ACE inhibitors may
not be mediated only within the kidney.group as compared with controls. These results could
also be explained by the modification of angiotensin II In summary, we demonstrated that the administration
of the ACE inhibitor enalapril attenuates the develop-effects on adhesion, migration, and proliferation of
mononuclear cells [42, 50]. ment of severe proteinuria, ameliorates morphological
lesions, and decreases leukocyte infiltration and theTheoretically, many effects of ACE inhibitors in vivo
can be attributed to an inhibition of the angiotensin II mRNA levels of growth factors and cytokines in the
process of chronic rejection. In the future, this class ofproduction [51–53]. In our experiment, angiotensinogen
was up-regulated when compared with controls. This drugs could prove efficient in clinical practice to reduce
the pace of chronic renal allograft rejection, thus increas-observation supports the report of Jonsson, Frewin, and
Head, who also demonstrated an up-regulation of angio- ing long-term renal allograft survival.
tensinogen following continuous administration of an
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